

Novel Fibroscan-Based Score to Diagnose NASH and its severity in A Multi-centre UK Cohort of Patients with Suspected NAFLD

Peter J. Eddowes², Quentin Anstee³, Indra Neil Guha⁴, David A. Sheridan⁶, Emmanouil Tsochatzis⁵, Jeremy Cobbold⁶, Michael E. Allison⁷, Victor de Ledinghen⁸, Magali Sasso¹, Celine Fournier⁹, Véronique Miette¹, Valerie Paradis¹⁰, Pierre Bedossa¹⁰, Philip N. Newsome²

1. R&D, Echosens, Paris, France

2. NIHR Birmingham Liver Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom

3. Institute of cellular medicine - Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom;

4. NIHR Nottingham Digestive Diseases Biomedical Research Unit, NHS Trust and University of Nottingham, Nottingham, United Kingdom

5. UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom

6. Department of Gastroenterology, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Oxford, United Kingdom;

7. Department of Hepatology, Addenbrookes Hospital, Cambridge, United Kingdom;

8. Centre d'Investigation de la Fibrose hépatique, Hôpital Haut-Lévêque, Centre Hospitalo-Universitaire de Bordeaux, Pessac, France

9. Medical Affairs, Echosens, Paris, France; 10. Pathology department, Hôpital Beaujon, APHP, Clichy, France

Background & Aims: Reliable non-invasive biomarkers are needed for the diagnosis and monitoring of patients with non-alcoholic steatohepatitis (NASH). Our study set out to determine the performance of a new score developed by Echosens to

differentiate NASH and simple steatosis based on a single Fibroscan examination (liver stiffness and controlled attenuation parameter (CAP)).

Methods: Patients with suspected NAFLD prospectively underwent FibroScan examination within 2 weeks of a standard of care liver biopsy (LB) between March 2014 and January 2016 at seven UK centers. LB were read in a blinded manner by two expert pathologists. NASH was diagnosed using the FLIP algorithm. NASH severity was graded according to the NAS score. To develop a score to diagnose NASH the cohort was split randomly into training (80%) and validation (20%) sets. Sample splitting was repeated 100 times leading to the selection of the optimum model. This was tested on an external validation cohort that consisted of 47 NAFLD patients from a single liver centre in France. Patients there underwent FibroScan examination within 1 day of LB, read by the same pathologists.

Results: 174 patients with BMI $<40 \text{ kg/m}^2$ were studied. The following patients were excluded for the score development: LB not interpretable/diagnostic of NAFLD (n=18), FibroScan not possible (n=1), FibroScan unreliable according to Boursier's criteria (n=10). Patients had a median BMI of 32.9 [IQR=6.9] kg/m^2 and age of 54 [21] years. 58% were male, 74% had a NAS score ≥ 3 and 58% had NASH. The external validation cohort had a median BMI of 30.0 [8.0] kg/m^2 and age of 53 [22] years. 67% were male, 82% had a NAS score ≥ 3 and 71% had NASH, 91% had a reliable Fibroscan examination. Performance of the scores is shown in the table.

Conclusion: A novel score based on measurement of liver stiffness and CAP from a single FibroScan examination was able to correctly classify 79% of patients with/without NASH as well as correctly staging severity in 86%. This has promise as a non-invasive marker for detecting/staging disease activity in patients with NASH.